GADOLINIUM-BASED COMPOUND AND MRI CONTRAST AGENT COMPRISING SAME
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Dec 5, 2024
app pub date -
Jul 21, 2022
filing date -
Jul 21, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
A gadolinium-based compound and an MRI contrast agent comprising same are disclosed. The gadolinium-based compound may be a DO3A-based gadolinium compound bound to protocatechuic acid. The MRI contrast agent may comprise the compound. In addition, disclosed is a pharmaceutical composition for preventing or treating neuroinflammatory diseases, comprising the compound or a pharmaceutically acceptable salt thereof.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully